Category: Corporate NewsBy adminMay 17, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX on BOD minutesNextNext post:EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture RemedsivirRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025Rameda One-Pager 1Q25May 13, 2025Earnings Release One-Pager 4Q24March 10, 2025Earning Release One Pager 3Q24November 14, 2024
